START ASSESSMENT

arrow

Movement is a vital part of life. Late-onset Pompe disease (LOPD), however, can slow you down and keep slowing you down even more with time. If you’re noticing a change in your ability to move, or ability to breathe, don’t wait to tell your healthcare provider. Because with time, progression can worsen and have life-changing impact. That’s why it’s important to talk about the next step in your Pompe journey.

The questions below can help you to evaluate how you’re doing, so that you can have a more informed conversation with your healthcare provider. As you answer the below, it’s important to reflect on even the smallest changes to help you stay ahead of Pompe.

Rank how you are feeling physically since your last checkup.

1 is same as last visit, and 10 is noticed a lot of change.

1
2
3
4
5
6
7
8
9
10
Since your last checkup, have you noticed a difference in

Check all that apply.

BREATHING

Breathing issues can cause
other symptoms as well.
Have you been experiencing more

MOVING

OTHER

Are you feeling more fatigued than usual?

1 is not more than usual, and 10 is feeling extreme fatigue.

1
2
3
4
5
6
7
8
9
10
Do you feel your current management plan is still helping your
late-onset Pompe disease?
Anything else you’ve noticed?

Please summarize for your healthcare provider.

If you feel like things have changed, trust your instincts and tell your healthcare provider. Together with your
healthcare provider, you can discuss if NEXVIAZYME is a treatment option that is right for you.

NEXVIAZYME is an enzyme replacement therapy that is a monotherapy*.
Find out if the NEX move is the right move for you.

*Not including pre-treatment or pre-medication.


NEXVIAZYME (avalglucosidase alfa-ngpt) is used for the treatment of patients 1 year of age and older with late-onset Pompe disease [lysosomal acid alpha-glucosidase (GAA) deficiency].

NEXVIAZYME is an enzyme replacement therapy that is a monotherapy*.
Find out if the NEX move is the right move for you. *Not including pre-treatment or pre-medication.


In a clinical study of 100 LOPD patients who had not been on treatment before, and who were given either NEXVIAZYME or alglucosidase alfa, NEXVIAZYME helped improve their breathing and walking distance as compared to when they began the study.

After 49 weeks on NEXVIAZYME, people were able to improve their breathing capacity by an average of 2.9 percentage points in a breathing test.* Those who took alglucosidase alfa improved their breathing by an average of 0.5 percentage points.* This resulting in a measurable improvement of 2.4 percentage points for people treated with NEXVIAZYME compared with people taking alglucosidase alfa, although it was not statistically superior.

People on NEXVIAZYME were also able to improve their walking distance by an average of 106 feet during a 6MWT.* The people taking alglucosidase alfa improved their walking distance by and average of 7.2 feet.* People taking NEXVIAZYME walked an average of 98 feet farther than those who were taking alglucosidase alfa. This measurement was not tested to determine statistical superiority of NEXVIAZYME to alglucosidase alfa. *Compared to when they began treatment.


What is the most important information about side effects that I should know about NEXVIAZYME (avalglucosidase alfa-ngpt)?

The information shown is highlighted from the Important Safety Information. Please scroll down to see more details.

NEXVIAZYME has caused serious side effects, including:

  • Hypersensitivity Reactions Including Anaphylaxis
  • Infusion-Associated
    Reactions (IARs)
  • Risk of Acute Cardiorespiratory Failure in Susceptible Patients

What are the possible side effects of NEXVIAZYME? Over the 49-week study, people taking NEXVIAZYME had fewer serious side effects than those taking alglucosidase alfa. No one had to stop taking NEXVIAZYME because of side effects, while 4 people had to stop taking alglucosidase alfa.

The most common side effects reported by people receiving NEXVIAZYME were headache, fatigue, diarrhea, nausea, joint pain, dizziness, muscle pain, itching, vomiting, shortness of breath, rash, “pins-and-needles” sensation, and hives.

These are the most common side effects, but there are other possible side effects. You should always tell your doctor about any changes in the way you feel, even if it’s not one of the listed side effects.

You can also report side effects at 1-800-FDA-1088 or www.fda.gov/medwatch.


When you have LOPD, the body does not have enough of the enzyme that breaks down glycogen in your muscle cells, so the glycogen builds up and causes muscle damage.

NEXVIAZYME has something called “high binding affinity” for a receptor in your muscle cell called M6PR. That receptor is like a lock on a door. A molecule called M6P is the key to open that lock. The NEXVIAZYME molecule has “keys” on its surface that fit in the “lock.” In fact, NEXVIAZYME has 15x the number of keys that alglucosidase alfa has. In a clinical study, NEXVIAZYME was not shown to be statistically superior to alglucosidase alfa.


NEXVIAZYME is given every 2 weeks by intravenous (IV) infusion. The recommended dosage of NEXVIAZYME is either 20 mg or 40 mg for each kilogram of body weight—your healthcare provider will calculate the appropriate dosage for you. The infusion usually takes approximately 4-5 hours for those receiving 20 mg/kg and between approximately 5-7 hours for those receiving 40 mg/kg. There could be additional time if you need any pretreatment. Also, infusion times may vary based on your response to therapy and comfort. Your healthcare provider will give you more details about what to expect during and after your infusion as well as how to prepare.

You’ll most likely want to bring a book, work, and/or electronic devices to make the most of your time. If you’re switching to NEXVIAZYME from alglucosidase alfa, your treatment schedule may stay the same.


For any other questions, please contact your Sanofi CareConnectPSS® Team 1‌-‌8‌00‌-‌745‌-‌4447, option 3.

We respect your right to privacy. Please note that we are not collecting the personal information you have provided.